Resistance to Nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions

被引:91
作者
Maga, G
Amacker, M
Ruel, N
Hubscher, U
Spadari, S [1 ]
机构
[1] CNR, IGBE, Inst Biochem & Evolutionary Genet, I-27100 Pavia, Italy
[2] Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland
关键词
reverse transcriptase; HIV-1; drug resistance; non-nucleoside inhibitors;
D O I
10.1006/jmbi.1997.1427
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The kinetic parameters governing the inhibition by Nevirapine of the RNA-dependent DNA synthesis catalyzed by HIV-1 reverse transcriptase have been determined by steady-state kinetic analysis with the wild-type enzyme and with mutant reverse transcriptases containing the single amino acid substitutions L100I, K103N, V106A, V179D, Y181I and Y188L. While the mutant V179D was inhibited by Nevirapine as the wild-type enzyme, all the other mutations displayed a 17 to 90-fold reduced sensitivity to the drug in the order: Y181I < (i.e. less sensitive) Y188L < V106A <L100I<K103N< wild-type. Determination of the rate constants for Nevirapine binding (k(on)) and dissociation (k(off)) for the mutant and wildtype enzymes showed that mutations L100I and V106A increased the k(off) values by 12 and 8.5-fold, respectively, without significantly affecting the k(on), whereas mutation K103N decreased the k(on) 5-fold without increasing the k(off). Mutations Y181I and Y188L, on the other hand, conferred resistance to Nevirapine affecting both k(on) and k(on) values. In addition, mutations L100I and Y181I reduced the catalytic potential of HIV-1 RT. Thus, Nevirapine resistance could arise from a combination of loss of stabilizing interactions and emergence of steric and thermodynamic barriers for drug binding, depending on the particular amino acid substitution involved. (C) 1997 Academic Press Limited.
引用
收藏
页码:738 / 747
页数:10
相关论文
共 37 条
[1]   Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors [J].
Balzarini, J ;
Pelemans, H ;
Karlsson, A ;
DeClercq, E ;
Kleim, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13152-13157
[2]  
Balzarini J, 1996, METHOD ENZYMOL, V275, P472
[3]   HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS SHOW DIFFERENTIAL ACTIVITY AGAINST HIV-1 MUTANT STRAINS CONTAINING DIFFERENT AMINO-ACID SUBSTITUTIONS IN THE REVERSE-TRANSCRIPTASE [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
VRANG, L ;
WALBERS, J ;
ZHANG, H ;
OBERG, B ;
VANDAMME, AM ;
CAMARASA, MJ ;
DECLERCQ, E .
VIROLOGY, 1993, 192 (01) :246-253
[4]   MUTATIONAL ANALYSIS OF THE FINGERS AND PALM SUBDOMAINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE [J].
BOYER, PL ;
FERRIS, AL ;
CLARK, P ;
WHITMER, J ;
FRANK, P ;
TANTILLO, C ;
ARNOLD, E ;
HUGHES, SH .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 243 (03) :472-483
[5]   ANALYSIS OF NONNUCLEOSIDE DRUG-RESISTANT VARIANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE [J].
BOYER, PL ;
CURRENS, MJ ;
MCMAHON, JB ;
BOYD, MR ;
HUGHES, SH .
JOURNAL OF VIROLOGY, 1993, 67 (04) :2412-2420
[6]   SUBUNIT SPECIFICITY OF MUTATIONS THAT CONFER RESISTANCE TO NONNUCLEOSIDE INHIBITORS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE [J].
BOYER, PL ;
DING, JP ;
ARNOLD, E ;
HUGHES, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :1909-1914
[7]   Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant [J].
Das, K ;
Ding, JP ;
Hsiou, Y ;
Clark, AD ;
Moereels, H ;
Koymans, L ;
Andries, K ;
Pauwels, R ;
Janssen, PAJ ;
Boyer, PL ;
Clark, P ;
Smith, RH ;
Smith, MBK ;
Michejda, CJ ;
Hughes, SH ;
Arnold, E .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) :1085-1100
[8]   HIV-1-SPECIFIC RT INHIBITORS - HIGHLY SELECTIVE INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAT ARE SPECIFICALLY TARGETED AT THE VIRAL REVERSE-TRANSCRIPTASE [J].
DECLERCQ, E .
MEDICINAL RESEARCH REVIEWS, 1993, 13 (03) :229-258
[9]   STRUCTURE OF HIV-1 REVERSE-TRANSCRIPTASE IN A COMPLEX WITH THE NONNUCLEOSIDE INHIBITOR ALPHA-APA-R-95845 AT 2.8-ANGSTROM RESOLUTION [J].
DING, J ;
DAS, K ;
TANTILLO, C ;
ZHANG, W ;
CLARK, AD ;
JESSEN, S ;
LU, X ;
HSIOU, Y ;
JACOBOMOLINA, A ;
ANDRIES, K ;
PAUWELS, R ;
MOEREELS, H ;
KOYMANS, L ;
JANSSEN, PAJ ;
SMITH, RH ;
KOEPKE, MK ;
MICHEJDA, CJ ;
HUGHES, SH ;
ARNOLD, E .
STRUCTURE, 1995, 3 (04) :365-379
[10]   STRUCTURE OF HIV-1 RT/TIBO R-86183 COMPLEX REVEALS SIMILARITY IN THE BINDING OF DIVERSE NONNUCLEOSIDE INHIBITORS [J].
DING, JP ;
DAS, K ;
MOEREELS, H ;
KOYMANS, L ;
ANDRIES, K ;
JANSSEN, PAJ ;
HUGHES, SH ;
ARNOLD, E .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (05) :407-415